Select Publications

Bukowski RM et al. Safety and efficacy of sorafenib in elderly patients (pts) ≥65 years: A subset analysis from the Advanced Renal Cell Carcinoma Sorafenib (ARCCS) Expanded Access Program in North America. Proc ASCO 2008;Abstract 5045.

Bukowski RM et al. Randomized phase II study of erlotinib combined with bevaci­zumab compared with bevacizumab alone in metastatic renal cell cancer. J Clin Oncol 2007;25(29):4536-41. Abstract

Figlin RA et al. Overall survival with sunitinib versus interferon (IFN)-alfa as first-line treatment of metastatic renal cell carcinoma (mRCC). Proc ASCO 2008;Abstract 5024.

Hudes G et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007;356(22):2271-81. Abstract

Melichar B et al. First-line bevacizumab combined with reduced dose interferon-{alpha} 2a is active in patients with metastatic renal cell carcinoma. Ann Oncol 2008;19(8):1470-6. Abstract

Motzer RJ et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356(2):115-24. Abstract

 

 

 

 

 

 

 

 

 

 

 

Home

Editor
Neil Love, MD

Interviews

Robert A Figlin, MD
- Select publications

Gary R Hudes, MD
- Select publications

Ronald M Bukowski, MD
- Select publications

CME Information

Faculty Disclosures

Editor's Office